# Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

> **NCT02279862** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 82 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02279862
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-02
- **Primary completion:** 2016-12-15
- **Final completion:** 2016-12-15
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279862, "Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02279862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*